Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HRT breast cancer link in dispute again

This article was originally published in Scrip

Executive Summary

The link between breast cancer risk and hormone replacement therapy (HRT) has been called into question again in an article published in the British Medical Journal's Journal of Family Planning and Reproductive Health Care. But some of the researchers who originally postulated the association argue that the latest publication only airs previously stated views, which have already been refuted, and they point to a large body of evidence for the causative link between HRT and breast cancer.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC015928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel